Ryan Chastant, MD
Otolaryngology · Lafayette, LANPI 1619118684
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,041 of the $4,241 with a category attached, or 71.7%. 27 manufacturers reported payments, led by Stryker at 34.7% of the total. Reporting peaked in 2019 at $1,968 and has fallen 76.3% since, to $467 in 2025.
Across 181 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$1K
- Optinose US, Inc.$532
- AbbVie$393
- Sanofi$369
- GSK$308
- Regeneron Healthcare Solutions, Inc.$184
- plus $983 from 21 others
What the payments were for
- Travel & lodging$1,10126%
- Food & beverage$3,04172%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 12 | $1,471 |
| Optinose US, Inc. | 48 | $532 |
| AbbVie(2 entities) | 22 | $393 |
| Sanofi | 20 | $369 |
| GSK | 19 | $308 |
| Regeneron Healthcare Solutions, Inc. | 7 | $184 |
| Intersect ENT, Inc. | 5 | $179 |
| Kaleo, Inc. | 9 | $124 |
| Aerin Medical Inc. | 9 | $110 |
| Acclarent, Inc | 4 | $79 |
| AstraZeneca | 5 | $60 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $55 |
| Itamar Medical Inc | 2 | $51 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $48 |
| Integra Lifesciences Corporation | 1 | $46 |
| Oyster Point Pharma, Inc. | 3 | $45 |
| Alk-abello, Inc | 2 | $35 |
| Phadia US Inc. | 1 | $28 |
| Johnson & Johnson | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Ambu Inc. | 1 | $14 |
| Organogenesis Inc. | 1 | $12 |
| Novartis | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Amgen | 1 | $12 |
| Galderma Laboratories, L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UNIVERSAL MID-FACE$1,043
- MINI PLATING SYSTEM (MPS)$109
- SINUVA$106
How this compares
$4,241 in reported general payments places this provider in the 80th percentile of 218 otolaryngology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Epinephrine | 26 | $5,809 |
| Fluticasone Propionate | 312 | $4,006 |
| Ipratropium Bromide | 78 | $2,620 |
| Azelastine Hcl | 86 | $2,490 |
| Cefdinir | 95 | $1,745 |
| Omeprazole | 105 | $1,094 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 48 | $528 |
| Mupirocin | 50 | $386 |
| Pantoprazole Sodium | 27 | $379 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 28 | $343 |
| Famotidine | 50 | $336 |
| Ondansetron OdtOndansetron | 59 | $295 |
| Methylprednisolone | 47 | $280 |
| Azithromycin | 30 | $223 |
| Montelukast Sodium | 21 | $96 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAEpinephrine | $16 | $5,80926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 218 otolaryngology providers in Louisiana.
Other otolaryngology in Lafayette
- Jesse DuplechainLafayette$29K
- James WhiteLafayette$11K
- David ForemanLafayette$5K
- Jason DurelLafayette$4K
- Maria DoucetLafayette$3K
- Donald GonzalesNew Orleans$351K
- Kevin McLaughlinCovington$186K
- Adil FatakiaMarrero$148K
- Edward McCoulNew Orleans$92K
- Michael YimShreveport$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.